Every material Form 8-K Obsidian Therapeutics, Inc. has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Obsidian Therapeutics completed its mergers with Galera Therapeutics on August 3, 2026, alongside a $350 million private placement. Legacy Obsidian holders now own about 51.6% of the combined company, Galera holders about 1.2%, and private placement investors about 47.2%, so existing shareholders are substantially diluted. The filing also says the company's 2025 going concern doubt and its prior losses remain risk factors.
Mergers consummated at 8:30 a.m. ET on August 3, 2026; the company was renamed Obsidian Therapeutics, Inc.
Concurrent PIPE Financing raised $350.0 million; about 29,165,559 shares were issued to investors.
Post-closing ownership: Legacy Obsidian about 51.6%, Legacy Galera about 1.2%, PIPE investors about 47.2%.
Shares expected to begin trading on Nasdaq under OBX on August 4, 2026; CVRs issued to Galera holders of record as of July 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Obsidian Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →